Do analysts recommend SSII or PDEX?

Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 8.07%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts clearly believe Pro-Dex is more favorable than SS Innovations International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SS Innovations International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pro-Dex 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable earnings & valuation, BVS or PDEX?

Bioventus has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.25 $22.73M $0.41 20.76 Pro-Dex $66.59M 3.10 $8.98M $3.62 17.89

Is BVS or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat Pro-Dex's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% Pro-Dex 16.08% 22.78% 14.30%

Does the media refer more to BVS or PDEX?

In the previous week, Pro-Dex had 3 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Pro-Dex and 3 mentions for Bioventus. Bioventus' average media sentiment score of 0.72 beat Pro-Dex's score of 0.18 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pro-Dex 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, CBLL or PDEX?

Pro-Dex has lower revenue, but higher earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 7.86 -$53.41M -$1.63 N/A Pro-Dex $66.59M 3.10 $8.98M $3.62 17.89

Is CBLL or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to CeriBell's net margin of -63.51%. Pro-Dex's return on equity of 22.78% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Pro-Dex 16.08% 22.78% 14.30%

Does the media favor CBLL or PDEX?

In the previous week, CeriBell had 3 more articles in the media than Pro-Dex. MarketBeat recorded 9 mentions for CeriBell and 6 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.18 beat CeriBell's score of -0.16 indicating that Pro-Dex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pro-Dex 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SGP or PDEX?

Pro-Dex has higher revenue and earnings than Spyglass Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A N/A N/A N/A Pro-Dex $66.59M 3.10 $8.98M $3.62 17.89

Which has stronger earnings and valuation, SIBN or PDEX?

Pro-Dex has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.11 -$18.90M -$0.39 N/A Pro-Dex $66.59M 3.10 $8.98M $3.62 17.89

Is SIBN or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to SiBone's net margin of -8.10%. Pro-Dex's return on equity of 22.78% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Pro-Dex 16.08% 22.78% 14.30%

Does the media refer more to SIBN or PDEX?

In the previous week, Pro-Dex had 2 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Pro-Dex and 4 mentions for SiBone. SiBone's average media sentiment score of 0.66 beat Pro-Dex's score of 0.18 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pro-Dex 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pro-Dex (PDEX) Competitors

$64.77 -2.73 (-4.04%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$64.21 -0.56 (-0.86%)

As of 05/29/2026 05:41 PM Eastern

Compare

PDEX vs. SSII, BVS, CBLL, SGP, and SIBN

Should you buy Pro-Dex stock or one of its competitors? MarketBeat compares Pro-Dex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pro-Dex include SS Innovations International (SSII), Bioventus (BVS), CeriBell (CBLL), Spyglass Pharma (SGP), and SiBone (SIBN). These companies are all part of the "medical equipment" industry.

How does Pro-Dex compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

SS Innovations International has a beta of -1.89, indicating that its share price is 289% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

In the previous week, Pro-Dex had 5 more articles in the media than SS Innovations International. MarketBeat recorded 6 mentions for Pro-Dex and 1 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 1.89 beat Pro-Dex's score of 0.18 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Overall Sentiment
SS Innovations International	Very Positive
Pro-Dex	Neutral

Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 8.07%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts clearly believe Pro-Dex is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has a net margin of 16.08% compared to SS Innovations International's net margin of -20.69%. Pro-Dex's return on equity of 22.78% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Pro-Dex	16.08%	22.78%	14.30%

15.3% of Pro-Dex shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pro-Dex has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	18.56	-$12.13M	-$0.05	N/A
Pro-Dex	$66.59M	3.10	$8.98M	$3.62	17.89

Summary

Pro-Dex beats SS Innovations International on 14 of the 16 factors compared between the two stocks.

How does Pro-Dex compare to Bioventus?

Bioventus (NASDAQ:BVS) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

In the previous week, Pro-Dex had 3 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Pro-Dex and 3 mentions for Bioventus. Bioventus' average media sentiment score of 0.72 beat Pro-Dex's score of 0.18 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pro-Dex	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventus currently has a consensus price target of $14.00, indicating a potential upside of 64.51%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 8.07%. Given Bioventus' stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 33.0% of Bioventus shares are owned by company insiders. Comparatively, 45.9% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bioventus has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.25	$22.73M	$0.41	20.76
Pro-Dex	$66.59M	3.10	$8.98M	$3.62	17.89

Bioventus has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Pro-Dex has a net margin of 16.08% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat Pro-Dex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Pro-Dex	16.08%	22.78%	14.30%

Summary

Bioventus beats Pro-Dex on 11 of the 17 factors compared between the two stocks.

How does Pro-Dex compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

CeriBell currently has a consensus target price of $22.20, suggesting a potential upside of 20.26%. Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 8.07%. Given CeriBell's stronger consensus rating and higher possible upside, equities analysts clearly believe CeriBell is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, CeriBell had 3 more articles in the media than Pro-Dex. MarketBeat recorded 9 mentions for CeriBell and 6 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.18 beat CeriBell's score of -0.16 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pro-Dex	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

Pro-Dex has lower revenue, but higher earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.86	-$53.41M	-$1.63	N/A
Pro-Dex	$66.59M	3.10	$8.98M	$3.62	17.89

Pro-Dex has a net margin of 16.08% compared to CeriBell's net margin of -63.51%. Pro-Dex's return on equity of 22.78% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Pro-Dex	16.08%	22.78%	14.30%

15.3% of Pro-Dex shares are owned by institutional investors. 20.1% of CeriBell shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Pro-Dex beats CeriBell on 9 of the 17 factors compared between the two stocks.

How does Pro-Dex compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Pro-Dex has a net margin of 16.08% compared to Spyglass Pharma's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Pro-Dex	16.08%	22.78%	14.30%

15.3% of Pro-Dex shares are held by institutional investors. 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Pro-Dex had 1 more articles in the media than Spyglass Pharma. MarketBeat recorded 6 mentions for Pro-Dex and 5 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.06 beat Pro-Dex's score of 0.18 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Spyglass Pharma	Positive
Pro-Dex	Neutral

Spyglass Pharma presently has a consensus target price of $45.00, indicating a potential upside of 133.64%. Pro-Dex has a consensus target price of $70.00, indicating a potential upside of 8.07%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Spyglass Pharma is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
Pro-Dex	$66.59M	3.10	$8.98M	$3.62	17.89

Summary

Pro-Dex beats Spyglass Pharma on 7 of the 11 factors compared between the two stocks.

How does Pro-Dex compare to SiBone?

SiBone (NASDAQ:SIBN) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Pro-Dex has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.11	-$18.90M	-$0.39	N/A
Pro-Dex	$66.59M	3.10	$8.98M	$3.62	17.89

SiBone currently has a consensus price target of $23.00, indicating a potential upside of 63.12%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 8.07%. Given SiBone's stronger consensus rating and higher probable upside, research analysts clearly believe SiBone is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has a net margin of 16.08% compared to SiBone's net margin of -8.10%. Pro-Dex's return on equity of 22.78% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Pro-Dex	16.08%	22.78%	14.30%

SiBone has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

98.1% of SiBone shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 3.9% of SiBone shares are held by company insiders. Comparatively, 45.9% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Pro-Dex had 2 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Pro-Dex and 4 mentions for SiBone. SiBone's average media sentiment score of 0.66 beat Pro-Dex's score of 0.18 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pro-Dex	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SiBone and Pro-Dex tied by winning 8 of the 16 factors compared between the two stocks.

Get Pro-Dex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDEX vs. The Competition

Export

Metric	Pro-Dex	MED/DENTAL Industry	Medical Sector	NASDAQ Exchange
Market Cap	$206.79M	$15.29B	$6.58B	$12.59B
Dividend Yield	N/A	1.23%	2.68%	5.31%
P/E Ratio	17.89	17.49	21.59	26.25
Price / Sales	3.10	2.28	561.77	114.93
Price / Cash	20.66	13.44	27.44	37.60
Price / Book	5.77	3.26	10.04	6.86
Net Income	$8.98M	$534.24M	$3.56B	$337.26M
7 Day Performance	1.97%	2.50%	2.85%	3.58%
1 Month Performance	29.18%	7.17%	4.59%	5.71%
1 Year Performance	66.08%	-0.54%	37.62%	39.70%

Pro-Dex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDEX Pro-Dex	2.2989 of 5 stars	$64.77 -4.0%	$70.00 +8.1%	+66.1%	$206.79M	$66.59M	17.89	140	Insider Trade
SSII SS Innovations International	1.2064 of 5 stars	$3.73 -4.1%	N/A	-35.1%	$778.51M	$42.49M	N/A	4	Positive News
BVS Bioventus	4.4587 of 5 stars	$9.02 -2.8%	$14.00 +55.2%	N/A	$775.20M	$568.09M	12.37	1,200
CBLL CeriBell	1.9972 of 5 stars	$18.80 +0.2%	$22.20 +18.1%	+9.9%	$712.18M	$89.06M	N/A	N/A	Analyst Upgrade Insider Trade
SGP Spyglass Pharma	N/A	$20.62 -1.1%	$45.00 +118.2%	N/A	$689.39M	N/A	N/A	65	Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDEX) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pro-Dex (PDEX) Competitors

PDEX vs. SSII, BVS, CBLL, SGP, and SIBN

How does Pro-Dex compare to SS Innovations International?

Summary

How does Pro-Dex compare to Bioventus?

Summary

How does Pro-Dex compare to CeriBell?

Summary

How does Pro-Dex compare to Spyglass Pharma?

Summary

How does Pro-Dex compare to SiBone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX vs. The Competition

Pro-Dex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pro-Dex (PDEX) Competitors

PDEX vs. SSII, BVS, CBLL, SGP, and SIBN

How does Pro-Dex compare to SS Innovations International?

Which has more volatility and risk, SSII or PDEX?

Does the media refer more to SSII or PDEX?

Do analysts recommend SSII or PDEX?

Is SSII or PDEX more profitable?

Do institutionals & insiders have more ownership in SSII or PDEX?

Which has better earnings & valuation, SSII or PDEX?

Summary

How does Pro-Dex compare to Bioventus?

Does the media refer more to BVS or PDEX?

Do analysts rate BVS or PDEX?

Do insiders & institutionals have more ownership in BVS or PDEX?

Which has preferable earnings & valuation, BVS or PDEX?

Which has more volatility and risk, BVS or PDEX?

Is BVS or PDEX more profitable?

Summary

How does Pro-Dex compare to CeriBell?

Do analysts prefer CBLL or PDEX?

Does the media favor CBLL or PDEX?

Which has more volatility and risk, CBLL or PDEX?

Which has stronger valuation & earnings, CBLL or PDEX?

Is CBLL or PDEX more profitable?

Do insiders and institutionals hold more shares of CBLL or PDEX?

Summary

How does Pro-Dex compare to Spyglass Pharma?

Is SGP or PDEX more profitable?

Do institutionals and insiders have more ownership in SGP or PDEX?

Does the media refer more to SGP or PDEX?

Do analysts prefer SGP or PDEX?

Which has higher valuation & earnings, SGP or PDEX?

Summary

How does Pro-Dex compare to SiBone?

Which has stronger earnings and valuation, SIBN or PDEX?

Do analysts recommend SIBN or PDEX?

Is SIBN or PDEX more profitable?

Which has more volatility and risk, SIBN or PDEX?

Do institutionals and insiders have more ownership in SIBN or PDEX?

Does the media refer more to SIBN or PDEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX vs. The Competition

Pro-Dex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools